<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385279</url>
  </required_header>
  <id_info>
    <org_study_id>ECRI-005</org_study_id>
    <nct_id>NCT02385279</nct_id>
  </id_info>
  <brief_title>Study Comparing the MiStent SES Versus the XIENCE EES Stent</brief_title>
  <acronym>DESSOLVE III</acronym>
  <official_title>Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECRI bv</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Micell Technologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stentys</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ECRI bv</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the performance of MISTENT to that of
      XIENCE in an all-comers patient population with symptomatic ischemic heart disease. The
      patients will be followed through 3 years for major clinical events.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non inferiority comparison of a device oriented composite endpoint (DOCE) or Target Lesion Failure (TLF) of the MISTENT group to the XIENCE group</measure>
    <time_frame>12 months postprocedure</time_frame>
    <description>TLF is a composite of clinical endpoint of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel and clinically-indicated target lesion revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>POCE defined as all-cause death, any Myocardial Infarction (MI), or any revascularization</measure>
    <time_frame>30 days, 6 months, 1 year, 2 years and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE defined as all-cause death, any MI, or any Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days, 6 months, 1 year, 2 years and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF) defined as cardiac death, TV MI, or clinically indicated TVR</measure>
    <time_frame>30 days, 6 months, 1 year, 2 years and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOCE/TLF defined as cardiac death, TV MI or clinically indicated Target Lesion Revascularization (TLR)</measure>
    <time_frame>30 days, 6 months, 2 years, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days, 6 months, 1 year, 2 years and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days, 6 months, 1 year, 2 years and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization</measure>
    <time_frame>30 days, 6 months, 1 year, 2 years and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rates according to ARC classification</measure>
    <time_frame>30 days, 6 months, 1 year, 2 years and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1404</enrollment>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>MiStent®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous Coronary Intervention with the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent. It is a balloon expandable sirolimus eluting stent with an absorbable polymer coating.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XIENCE EES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MiStent</intervention_name>
    <description>Percutaneous Coronary Intervention</description>
    <arm_group_label>MiStent®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE EES</intervention_name>
    <description>Percutaneous Coronary Intervention</description>
    <arm_group_label>XIENCE EES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All comers&quot; patients:

          -  Male or female patients 18 years or older;

          -  Presence of one or more coronary artery stenoses of 50% or more in a native coronary
             artery or in a saphenous venous or arterial bypass conduit suitable for coronary stent
             implantation.

          -  The vessel should have a reference vessel diameter ranging from 2.5 mm to 3.75 mm (no
             limitation on the number of treated lesions, vessels, or lesion length); All lesions
             of the patient must comply with the angiographic inclusion criteria.

          -  The patient is judged to be capable of providing voluntary informed consent and has
             been fully informed of the nature of the study, is willing to comply with all study
             requirements and will provide written informed consent as approved by the Ethics
             Committee of the respective clinical site.

        Exclusion Criteria:

          -  Known pregnancy or breastfeeding at time of randomization;

          -  Known contraindication or hypersensitivity to sirolimus, everolimus, cobalt-chromium,
             or to medications such as aspirin, heparin, bivalirudin, and all of the following four
             medications: clopidogrel bisulfate, ticlopidine, prasugrel, ticagrelor;

          -  Concurrent medical condition with a life expectancy of less than 12 months.

          -  The patient is unwilling/ not able to return for outpatient clinic at 1 month and 12
             months follow-up.

          -  Currently participating in another trial and not yet at its primary endpoint.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerrit-Anne van Es</last_name>
    <role>Study Director</role>
    <affiliation>ECRI bv</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. W. Serruys, Prof. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Center for Circulatory Health, NHLI, Imperial College, London, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W Wijns, Prof. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartcenter, OLV Aalst, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. de Winter, Prof. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum, Amsterdam, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Center Corbeil</name>
      <address>
        <city>Corbeil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Nimes</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Munster</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Wiesbaden</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Amersfoort</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooi</name>
      <address>
        <city>Blaricum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Emmen</name>
      <address>
        <city>Emmen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Venlo</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Belchatow</name>
      <address>
        <city>Belchatow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Bielsko-Biala</name>
      <address>
        <city>Bielsko-Biala</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research center Chrzanow</name>
      <address>
        <city>Chrzanow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Tychy</name>
      <address>
        <city>Tychy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center Zgierz</name>
      <address>
        <city>Zgierz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAD</keyword>
  <keyword>ACS</keyword>
  <keyword>All comers</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

